Lilly's Q2 Beat Raises Guidance, But Foundayo Silence Leaves Oral Equation Incomplete

What happened

Eli Lilly reported Q2 2026 revenue of $23.0 billion, up 48% year over year, driven by Mounjaro and Zepbound volume, surpassing consensus expectations. The company raised full-year guidance, with non-GAAP EPS of $8.38 reflecting 33% growth, demonstrating that injectable demand still runs hot despite known pricing headwinds. However, the press release is silent on Foundayo, the oral GLP-1 pill that DeepValue identified as the key catalyst for reacceleration, leaving investors to parse the conference call for launch metrics. With the stock already trading near $1,178, above our attractive entry of $1,050, the results validate the core thesis but do not yet resolve the oral adoption question that keeps us on the sidelines. The next checkpoint is management's commentary on script trends and the 2027 outlook at the December investor meeting, which will determine whether the premium multiple can be sustained.

Implication

For investors, Q2 results confirm that Lilly's injectable franchise remains the dominant force in obesity, with volume growth strong enough to overcome double-digit price declines. The guidance raise signals confidence in the back half of 2026, likely reflecting ongoing Zepbound and Mounjaro momentum plus initial Medicare bridge contributions. Yet, the absence of Foundayo figures in the press release is telling—the market still lacks concrete proof that the oral pill is gaining traction commensurate with its valuation premium. At 41.7x trailing earnings, any disappointment in oral ramp or retatrutide timing could trigger sharp multiple compression, as outlined in our bear case ($950). We maintain our WAIT rating until we see sustained Foundayo script acceleration above 40,000 weekly, a level that would demonstrate the access expansion is converting into durable demand.

Thesis delta

The strong Q2 print reduces the near-term severity of our bear scenario but does not alter the central thesis that Foundayo's oral launch remains the pivotal variable for re-rating. While the injectable business is firing on all cylinders, the stock already prices in a successful oral rollout, and without tangible script data, the WAIT call stands. We are now slightly more confident that downside is limited, but we require clearer evidence of oral adoption before upgrading our stance.